Literature DB >> 18520950

Effect of mast cell stabilizers in hyperhomocysteinemia-induced cardiac hypertrophy in rats.

Amrit Pal Singh1, Manjeet Singh, Pitchai Balakumar.   

Abstract

BACKGROUND: The present study has been designed to investigate the effect of sodium cromoglycate and ketotifen, mast cell stabilizers in hyperhomocysteinemia-induced cardiac hypertrophy in rats.
METHODS: Rats were administered L-methionine (1.7 g/kg/day PO) for 8 weeks to produce hyperhomocysteinemia. Sodium cromoglycate (24 mg/kg/day IP) and ketotifen (1mg/kg/day IP) treatments were started from first day of administration of L-methionine and continued for 8 weeks. The development of cardiac hypertrophy was assessed in terms of measuring mean arterial blood pressure (MABP), ratio of left ventricular (LV) weight to body weight (LVW/BW), LV wall thickness (LVWT), LV protein content, and LV collagen content. Further, the oxidative stress in heart was assessed by measuring lipid peroxidation, superoxide anion generation, and reduced glutathione (GSH). Moreover, the cardiomyocyte diameter and LV mast cell density were determined using hematoxylin-eosin and toluidine blue staining, respectively.
RESULTS: The L-methionine administration produced hyperhomocysteinemia, which significantly increased MABP, oxidative stress, and density of mast cells and consequently produced cardiac hypertrophy by increasing cardiomyocyte diameter, LVW/BW, LVWT, LV protein and collagen content. However, sodium cromoglycate and ketotifen treatments significantly attenuated hyperhomocysteinemia-induced oxidative stress and pathological cardiac hypertrophy without significantly altering MABP. Moreover, sodium cromoglycate and ketotifen treatments did not affect serum homocysteine levels.
CONCLUSIONS: Thus, it may be concluded that hyperhomocysteinemia-induced cardiac hypertrophy is associated with an increase in oxidative stress and density of mast cells in heart. Sodium cromoglycate and ketotifen may have attenuated hyperhomocysteinemia-induced pathological cardiac hypertrophy, possibly by reducing oxidative stress and preventing the degranulation and increase in density of mast cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18520950     DOI: 10.1097/FJC.0b013e31817ae60f

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  9 in total

1.  Effects of mast cell modulation on early host response to implanted synthetic meshes.

Authors:  S B Orenstein; E R Saberski; U Klueh; D L Kreutzer; Y W Novitsky
Journal:  Hernia       Date:  2010-06-05       Impact factor: 4.739

2.  Simvastatin inhibited cardiac hypertrophy and fibrosis in apolipoprotein E-deficient mice fed a "Western-style diet" by increasing PPAR α and γ expression and reducing TC, MMP-9, and Cat S levels.

Authors:  Yan-wen Qin; Ping Ye; Ji-qiang He; Li Sheng; Lu-ya Wang; Jie Du
Journal:  Acta Pharmacol Sin       Date:  2010-09-13       Impact factor: 6.150

Review 3.  Mast cell chymase and tryptase as targets for cardiovascular and metabolic diseases.

Authors:  Aina He; Guo-Ping Shi
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

4.  Synergism in hyperhomocysteinemia and diabetes: role of PPAR gamma and tempol.

Authors:  Paras K Mishra; Neetu Tyagi; Utpal Sen; Irving G Joshua; Suresh C Tyagi
Journal:  Cardiovasc Diabetol       Date:  2010-09-09       Impact factor: 9.951

5.  Mast cell inhibition attenuates myocardial damage, adverse remodeling, and dysfunction during fulminant myocarditis in the rat.

Authors:  Yair Mina; Shunit Rinkevich-Shop; Eli Konen; Orly Goitein; Tammar Kushnir; Frederick H Epstein; Micha S Feinberg; Jonathan Leor; Natalie Landa-Rouben
Journal:  J Cardiovasc Pharmacol Ther       Date:  2012-11-19       Impact factor: 2.457

Review 6.  Do resident renal mast cells play a role in the pathogenesis of diabetic nephropathy?

Authors:  Pitchai Balakumar; Jayarami Reddy; Manjeet Singh
Journal:  Mol Cell Biochem       Date:  2009-05-05       Impact factor: 3.396

7.  Involvement of mast cells in monocrotaline-induced pulmonary hypertension in rats.

Authors:  Bhola K Dahal; Djuro Kosanovic; Christina Kaulen; Teodora Cornitescu; Rajkumar Savai; Julia Hoffmann; Irwin Reiss; Hossein A Ghofrani; Norbert Weissmann; Wolfgang M Kuebler; Werner Seeger; Friedrich Grimminger; Ralph T Schermuly
Journal:  Respir Res       Date:  2011-05-02

8.  Hyperhomocysteinemia accompany with metabolic syndrome increase the risk of left ventricular hypertrophy in rural Chinese.

Authors:  Shasha Yu; Yintao Chen; Hongmei Yang; Xiaofan Guo; Liqiang Zheng; Yingxian Sun
Journal:  BMC Cardiovasc Disord       Date:  2020-02-03       Impact factor: 2.298

9.  New dynamic viewing of mast cells in pulmonary arterial hypertension (PAH): contributors or outsiders to cardiovascular remodeling.

Authors:  Jian Xu; Jingjing Wang; Chengjie Shao; Xiaoning Zeng; Lixiang Sun; Hui Kong; Weiping Xie; Hong Wang
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.